Top Ten most popular articles on Pharmafile.com this week!
pharmafile | November 9, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Celgene, GSK, Novo Nordisk, politics, popular, top 10, vaccines
The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was able to eliminate 99% of the HIV virus within four weeks in phase 1/2a clinical trials.
Meanwhile former Celgene CEO Bob Hugin failed in his bid for electoral victory after Democrat Bob Menendez won over the people of New Jersey in the US midterms. In sticking to politics our feature ‘Vaccines in the age of populism’ discusses the rise of anti-establishment politics and the effect it has on patient adherence.
Check out this week’s top ten most popular stories on Pharmafile.com!
10. Anti-vaxxers: Vaccines in the age of populism
Mistrust of the establishment has fuelled anti-vaccine sentiment in recent years, and adherence has waned as a result. Louis Goss looks into the roots of the anti-vaccine movement and asks what might be done to heal the wound
9.Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes
Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint and “significantly reduced” the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus.
8. AbbVie sue NHS over hepatitis C drug procurement
American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached procurement rules.
7. Former Celgene CEO Bob Hugin loses in US midterm elections
Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters last night elected Democratic candidate Bob Menendez in the US midterm elections.
6. J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn
Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal worth up to $1.2 billion.
5. AstraZeneca sells off three drugs in deal worth $350 million
Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 million (£268 million).
Danish multinational Novo Nordisk has said that they will have cut 1,300 employees by the end of 2018. The decision has come partly in response to the Trump administration’s efforts to reduce the price of drugs, according to Novo Nordisk CEO Lars Fruergaard Jørgensen.
3. GSK’s anti-seizure drug shows promise in early depression study
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications as a treatment for treatment-resistant depression.
2. FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma, it has emerged.
1. HIV drug reduces viral load by 99% within 4 weeks
HIV-drug Gammora may eliminate 99% of the HIV virus within four weeks of treatment, according to the results of a Phase 1/2a clinical trial, conducted by Israeli biotech Zion Medical.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
